Brodalumab: A Review in Moderate to Severe Plaque Psoriasis
Author:
- 8 March 2018
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 78 (4) , 495-504
Abstract
Brodalumab (Kyntheum®) is a human anti-interleukin-17 receptor A (IL-17RA) monoclonal antibody available for use in patients with moderate to severe plaque psoriasis. In the phase III AMAGINE trials in this patient population, 12 weeks of induction therapy with subcutaneous brodalumab was superior to placebo in terms of the proportion of patients with ≥ 75% improvement in the Psoriasis Area and Severity Index score (PASI 75) and the proportion of patients with a static Physician Global Assessment score of 0 or 1. Brodalumab was also superior to ustekinumab for PASI 100 (i.e. complete skin clearance) at week 12. Health-related quality of life (HR-QOL) outcomes improved to a significantly greater extent with brodalumab than with placebo. Moreover, brodalumab was more effective than placebo in patients with difficult-to-treat nail or scalp psoriasis. Brodalumab was generally well tolerated, with low rates of immunogenicity. Efficacy was sustained and brodalumab remained well tolerated during up to 52 weeks of maintenance therapy. Thus, subcutaneous brodalumab is a useful addition to the treatment options currently available for patients with moderate to severe plaque psoriasis.Keywords
This publication has 21 references indexed in Scilit:
- Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive ReviewAmerican Journal of Clinical Dermatology, 2015
- European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPCJournal of the European Academy of Dermatology and Venereology, 2015
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisNew England Journal of Medicine, 2015
- The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European CountriesJournal of Investigative Dermatology, 2015
- Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studiesThe Journal of Clinical Pharmacology, 2014
- Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal AntibodyThe Journal of Immunology, 2014
- Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled TrialJournal of Investigative Dermatology, 2012
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for PsoriasisNew England Journal of Medicine, 2012
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010